Meeting at J.P. Morgan 2024?
Looking for partnering or investment with Oncoteq? CEO Mads Dalsgaard, CFO Swati Mehta, and CBO Sarah Holland will be attending so please reach out to set up meeting in San Francisco
Oncoteq completes another in-licensing deal, adding a potential best-in-class CD30 antibody drug conjugate from Tubulis to its oncology pipeline
Oncoteq AG (Oncoteq), a clinical stage biotech company specializing in novel and innovative cancer treatments, is expanding its development pipeline by in-licensing the potential best-in-class antibod ...
Oncoteq expands pipeline with TEQ103 , a promising treatment for breast cancer
Today we announce the second in-licensing deal as we obtain a world-wide exclusive license to a novel compound with potential to shift the paradigm in breast cancer treatment. The first-in-class compo ...
Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets DURHAM, N.C. ...
Liliana Diaz joins Oncoteq as Director Technical Development
We are pleased to welcome Liliana Diaz to the Oncoteq team as Director Technical Development. Liliana Diaz brings 25 years of experience in the pharmaceutical industry in different CMC roles, with foc ...
Angelo Guainazzi joins Oncoteq as Program Lead
We are very pleased to welcome Angelo Guainazzito the Oncoteq team as Global Program Leader. Angelo brings over a decade of experience in clinical drug development in mainly oncology and neurological ...
Cureteq’s CBO, Sarah Holland, interviewed about career, the role of CBO and Cureteq.
In the latest interview article from Sejelas, Cureteq’s Chief Business Officer, Sarah Holland, shares her career story and her take on the role of Chief Business Officer and about Cureteq.
Inessa Polyakova joins Oncoteq AG as Global Development Medical Director
We are very pleased to welcome Innessa Polyakova brings over 18 years of experience in clinical research, medical monitoring and drug development in hematology and oncology from across biotech and sma ...
Steven Mortier joins Oncoteq AG as Global Program Leader
We are pleased to inform you that Steven Mortier is joining us at Oncoteq AG, as Global Program Leader. Steven Mortier brings more than two decades of experience from clinical drug development and pro ...
Sarah Holland appointed as Chief Business Officer
Sarah Holland joins the Cureteq team as Chief Business Officer. Sarah brings over 30 years of biopharma industry experience, spanning the full value chain from R&D, Commercial and Business Develop ...
Dr. Andreas Penk joins the Board of Directors at Cureteq AG
We are very pleased to announce that Dr. Andreas Penk joins the Board of Directors at Cureteq AG. Andreas Penk, MD by education, is a former Senior Executive with Pfizer, most recently as President, P ...
Cureteq present at the ESMO Conference
Busy and informative days at Conference, ESMO – European Society for Medical Oncology – in Paris; with our sister company and strategic partner Innoplexus.Always motivating to submerge in ...